. Author manuscript; available in PMC: 2020 May 7.

Published in final edited form as: Ann Intern Med. 2019 Apr 9;170(9):594–603. doi: 10.7326/M18-1715

Appendix Table 2.

SVR, by Treatment Regimen^*

Regimen	Patients, n	SVR, n (%)	SVR, 95% CI, %
SOF/LDV	104	98 (94)	88–98
SOF/SMV	11	11 (100)	72–100
SOF/IFN/RBV	15	14 (93)	68–100
SOF/RBV	17	15 (88)	64–99
TVR/IFN/RBV	3	3 (100)	29–100
Total	150	141 (94)	89–97

IFN = pegylated interferon; LDV = ledipasvir; RBV = ribavirin; SMV = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; TVR = telaprevir.

No significant differences in SVR were found among treatment regimens (P = 0.69). No missing data were observed for this analysis.